Matches in SemOpenAlex for { <https://semopenalex.org/work/W3014545702> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W3014545702 endingPage "83" @default.
- W3014545702 startingPage "77" @default.
- W3014545702 abstract "Aim: <i>Escherichia coli</i> is one of the Gram-negative bacteria, known to cause many nosocomial infections. Multi-drug (MDR) and extensively-drug resistant (XDR). <i>E. coli</i> are of particular note, due to significant limitations in antibiotic therapy. Ceftolozane-tazobactam and ceftazidime-avibactam are novel therapeutic options against Gram-negative bacteria; hence the aim of this study was to evaluate and compare the <i> in vitro </i> activity of ceftolozane-tazobactam and ceftazidime-avibactam against MDR and XDR clinical <i>E. coli</i> isolates. Material/Methods: The study included 100 non-replicate <i>E. coli</i> isolates derived from clinical samples of patients hospitalized in teaching hospitals. Bacteria were identified by applying mass spectrometry in the MALDI Biotyper system (Bruker). ESBL (bla<sub>CTX-M-1group</sub>, bla<sub>CTX-M-9group</sub>) and carbapenemase (bla<sub>KPC</sub>, bla<sub>VIM</sub>, bla<sub>NDM</sub>, bla<sub>OXA-48</sub>, bla<sub>OXA-181</sub>) genes were detected using the eazyplex® SuperBug CRE test, based on a loop-mediated isothermal amplification (LAMP). The in vitro susceptibility to ceftolozane-tazobactam and ceftazidime-avibactam was tested using validated MIC Test strips (Liofilchem). Results: All 84 extended-spectrum β-lactamase-producing (ESBL) <i>E. coli</i> isolates were susceptible to ceftazidime-avibactam and 83 to ceftolozane-tazobactam. Among 17 <i>E. coli</i> isolates with resistance to at least one of the carbapenems, three (17.6%) were susceptible to ceftolozane-tazobactam and ceftazidime-avibactam. All 14 blaVIM gene-positive <i>E. coli</i> isolates were resistant to both ceftolozane-tazobactam and ceftazidime-avibactam. Both antibiotics were active against bla<sub>CTX-M-9group</sub> and bla<sub>OXA-48</sub> gene-positive <i>E. coli</i> isolates, but they were not active against bla<sub>CTX-M-1group</sub> and bla<sub>VIM</sub> gene-positive isolates. Conclusions: Ceftolozane-tazobactam and ceftazidime-avibactam are alternative, non-carbapenem therapeutic options for ESBL-positive <i>E. coli</i> strains, and they are promising in the treatment of carbapenem-resistant <i>E. coli</i> strains, but not for those carrying the metallo-β-lactamase enzymes. Both drug combinations have comparable activity against ESBL, however, lower MIC values were found for ceftazidime-avibactam." @default.
- W3014545702 created "2020-04-10" @default.
- W3014545702 creator A5010165837 @default.
- W3014545702 creator A5016012684 @default.
- W3014545702 date "2020-04-03" @default.
- W3014545702 modified "2023-10-16" @default.
- W3014545702 title "Antimicrobial susceptibility of multi-drug and extensively-drug-resistant Escherichia coli to ceftolozane-tazobactam and ceftazidime-avibactam: An in vitro study*" @default.
- W3014545702 cites W1987072535 @default.
- W3014545702 cites W2053394749 @default.
- W3014545702 cites W2793495265 @default.
- W3014545702 doi "https://doi.org/10.5604/01.3001.0014.0859" @default.
- W3014545702 hasPublicationYear "2020" @default.
- W3014545702 type Work @default.
- W3014545702 sameAs 3014545702 @default.
- W3014545702 citedByCount "1" @default.
- W3014545702 countsByYear W30145457022022 @default.
- W3014545702 crossrefType "journal-article" @default.
- W3014545702 hasAuthorship W3014545702A5010165837 @default.
- W3014545702 hasAuthorship W3014545702A5016012684 @default.
- W3014545702 hasConcept C104317684 @default.
- W3014545702 hasConcept C114851261 @default.
- W3014545702 hasConcept C185592680 @default.
- W3014545702 hasConcept C2775933652 @default.
- W3014545702 hasConcept C2776968632 @default.
- W3014545702 hasConcept C2777406300 @default.
- W3014545702 hasConcept C2777637488 @default.
- W3014545702 hasConcept C2778266534 @default.
- W3014545702 hasConcept C2779631663 @default.
- W3014545702 hasConcept C501593827 @default.
- W3014545702 hasConcept C523546767 @default.
- W3014545702 hasConcept C54355233 @default.
- W3014545702 hasConcept C547475151 @default.
- W3014545702 hasConcept C55493867 @default.
- W3014545702 hasConcept C71924100 @default.
- W3014545702 hasConcept C86803240 @default.
- W3014545702 hasConcept C89423630 @default.
- W3014545702 hasConcept C94665300 @default.
- W3014545702 hasConceptScore W3014545702C104317684 @default.
- W3014545702 hasConceptScore W3014545702C114851261 @default.
- W3014545702 hasConceptScore W3014545702C185592680 @default.
- W3014545702 hasConceptScore W3014545702C2775933652 @default.
- W3014545702 hasConceptScore W3014545702C2776968632 @default.
- W3014545702 hasConceptScore W3014545702C2777406300 @default.
- W3014545702 hasConceptScore W3014545702C2777637488 @default.
- W3014545702 hasConceptScore W3014545702C2778266534 @default.
- W3014545702 hasConceptScore W3014545702C2779631663 @default.
- W3014545702 hasConceptScore W3014545702C501593827 @default.
- W3014545702 hasConceptScore W3014545702C523546767 @default.
- W3014545702 hasConceptScore W3014545702C54355233 @default.
- W3014545702 hasConceptScore W3014545702C547475151 @default.
- W3014545702 hasConceptScore W3014545702C55493867 @default.
- W3014545702 hasConceptScore W3014545702C71924100 @default.
- W3014545702 hasConceptScore W3014545702C86803240 @default.
- W3014545702 hasConceptScore W3014545702C89423630 @default.
- W3014545702 hasConceptScore W3014545702C94665300 @default.
- W3014545702 hasLocation W30145457021 @default.
- W3014545702 hasOpenAccess W3014545702 @default.
- W3014545702 hasPrimaryLocation W30145457021 @default.
- W3014545702 hasRelatedWork W1800273246 @default.
- W3014545702 hasRelatedWork W2261913017 @default.
- W3014545702 hasRelatedWork W2301543346 @default.
- W3014545702 hasRelatedWork W2339454548 @default.
- W3014545702 hasRelatedWork W2575028928 @default.
- W3014545702 hasRelatedWork W2739079221 @default.
- W3014545702 hasRelatedWork W2901057130 @default.
- W3014545702 hasRelatedWork W2972310482 @default.
- W3014545702 hasRelatedWork W3197001659 @default.
- W3014545702 hasRelatedWork W4324148845 @default.
- W3014545702 hasVolume "74" @default.
- W3014545702 isParatext "false" @default.
- W3014545702 isRetracted "false" @default.
- W3014545702 magId "3014545702" @default.
- W3014545702 workType "article" @default.